OnKure Therapeutics, Inc. (OKUR): who owns it and who trades it
As of Nov 16, 2026, OKUR insiders reported 8 open-market sales worth $5.6K and no purchases in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jason A. Leverone (CFO), with $4.4K. 2 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling OnKure Therapeutics
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns OKUR
76 funds and institutions reported OKUR shares worth $160M at the end of Q2 2026, about 86% of the company. The largest holder is Ra Capital Management, L.P. with 9.9%.
Funds and institutions (13F) 86%Everyone else 14%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 4.00M | 9.87% | $18.2M | No change |
| Bvf Inc | 3.24M | 7.99% | $14.8M | +64% |
| Acorn Capital Advisors, LLC | 2.84M | 7.01% | $12.9M | No change |
| StepStone Group LP | 2.66M | 6.57% | $12.1M | No change |
| ADAR1 Capital Management, LLC | 2.24M | 5.53% | $10.2M | -8% |
| Vivo Capital, LLC | 1.93M | 4.76% | $8.8M | No change |
| Vestal Point Capital, LP | 1.83M | 4.51% | $8.3M | -1% |
| BlackRock, Inc. | 1.50M | 3.70% | $6.8M | +2925% |
| Trails Edge Capital Partners, LP | 1.44M | 3.55% | $6.6M | New |
| Vanguard Capital Management LLC | 1.44M | 3.55% | $6.6M | +147% |
| Adage Capital Partners Gp, L.l.c. | 1.20M | 2.97% | $5.5M | No change |
| Citadel Advisors LLC | 1.19M | 2.93% | $5.4M | +3058% |
| Sio Capital Management, LLC | 1.08M | 2.66% | $4.9M | No change |
| Prosight Management, LP | 978,992 | 2.42% | $4.5M | -55% |
| Logos Global Management LP | 963,855 | 2.38% | $4.4M | New |
| Geode Capital Management, LLC | 724,438 | 1.79% | $3.3M | +634% |
| NEA Management Company, LLC | 478,548 | 1.18% | $2.2M | No change |
| State Street Corp | 463,662 | 1.14% | $2.1M | +3344% |
| Ensign Peak Advisors, Inc | 431,631 | 1.07% | $2M | New |
| Renaissance Technologies LLC | 358,738 | 0.89% | $1.6M | -5% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, OKUR insiders reported $0 of open-market purchases and $5.6K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026 | Nicholas A Saccomano | CEO | Sale | 87 | $2.97 | $258 | Form 4 |
| Sep 21, 2026 | Jason A. Leverone | CFO | Sale | 302 | $2.97 | $897 | Form 4 |
| Jun 22, 2026 | Nicholas A Saccomano | CEO | Sale | 86 | $4.40 | $378 | Form 4 |
| Jun 22, 2026 | Jason A. Leverone | CFO | Sale | 303 | $4.40 | $1.3K | Form 4 |
| Mar 23, 2026 | Nicholas A Saccomano | CEO | Sale | 86 | $4.16 | $358 | Form 4 |
| Mar 23, 2026 | Jason A. Leverone | CFO | Sale | 301 | $4.16 | $1.3K | Form 4 |
| Dec 22, 2025 | Nicholas A Saccomano | CEO | Sale | 87 | $2.97 | $258 | Form 4 |
| Dec 22, 2025 | Jason A. Leverone | CFO | Sale | 302 | $2.97 | $897 | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jason A. Leverone | Chief Financial Officer | – | $4.4K | Sep 21, 2026 |
| Nicholas A Saccomano | President and CEO, Director | – | $1.3K | Sep 21, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
OKUR short interest
Low short interest. 3.2% of OKUR shares are sold short: about 1 share in 31. Over the last 12 reports the number of shares short went up 551%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 1.30M OKUR shares were sold short, 3.2% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 306,010 shares, buying them all back would take about 4.2 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.30M | 3.21% | -6% | 306,010 | 4.2 |
| Oct 15, 2026 | 1.39M | 3.42% | +13% | 543,501 | 2.5 |
| Sep 30, 2026 | 1.22M | 3.02% | -11% | 257,074 | 4.8 |
| Sep 15, 2026 | 1.38M | 3.40% | +4% | 148,214 | 9.3 |
| Aug 31, 2026 | 1.32M | 3.26% | +23% | 171,764 | 7.7 |
| Aug 14, 2026 | 1.07M | 2.65% | -10% | 134,805 | 8.0 |
| Jul 31, 2026 | 1.19M | 8.68% | +0% | 112,263 | 10.6 |
| Jul 15, 2026 | 1.18M | 8.64% | +34% | 204,025 | 5.8 |
| Jun 30, 2026 | 878,668 | 6.43% | +211% | 755,793 | 1.2 |
| Jun 15, 2026 | 282,400 | 2.07% | +20% | 379,774 | 1.0 |
| May 29, 2026 | 234,931 | 1.72% | +18% | 216,246 | 1.1 |
| May 15, 2026 | 199,392 | 1.46% | +93% | 142,174 | 1.4 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
OnKure Therapeutics company events
OnKure Therapeutics filed 7 reports on Form 8-K in the last 12 months, 3 of them about an important change (leadership). The latest was on Nov 4, 2026.
- Nov 4, 2026ResultsReleased financial results. Filing
- Aug 13, 2026LeadershipThe Board of Directors of OnKure Therapeutics, Inc. approved an option repricing. Filing
- Aug 4, 2026ResultsReleased financial results. Filing
- Jun 4, 2026LeadershipOnKure Therapeutics, Inc. amended and restated its 2024 Equity Incentive Plan, effective as of June 3, 2026 upon approval by the stockholders of the Company at the Annual Meeting (as defined below). Filing
- May 5, 2026ResultsReleased financial results. Filing
- Mar 30, 2026LeadershipIn connection with the Private Placement, the Board elected Dr. Liam Ratcliffe as a Class I director of the Company, effective and contingent on the closing of the Private Placement. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
OnKure Therapeutics financials
Famous investors that hold OKUR
2 of the 50 well-known investors we track reported holding OKUR in their latest 13F filing. The largest position is Ken Griffin's, worth $1.5M.
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 556,493 | $1.5M | 0.0% | -53% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 353,150 | $962K | 0.0% | -2% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named OKUR in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 5.2% |
| Nov 16, 2026 | BIOTECHNOLOGY VALUE FUND L P | 13G/A | 5.2% |
| Oct 7, 2026 | Coastlands Capital LP | 13G | 6.7% |
| Oct 7, 2026 | Coastlands Capital LP | 13G | 6.7% |
Questions about OnKure Therapeutics, Inc. (OKUR) stock
Who owns the most OKUR stock?
The largest reported owner of OnKure Therapeutics, Inc. (OKUR) is Ra Capital Management, L.P., with 9.9% of the company. In total, 76 funds and institutions reported holding OKUR at the end of Q2 2026, together about 86% of the shares. See the largest owners.
Are OKUR insiders buying or selling?
In the last 12 months, OKUR insiders reported no open-market purchases and 8 sales worth $5.6K. The latest trade was on Sep 21, 2026. See every trade.
What is the short interest in OKUR?
As of Oct 30, 2026, 1.30M OKUR shares were sold short, 3.2% of the shares outstanding, down 6.3% from the report before. At the average daily volume of 306,010 shares, buying them all back would take about 4.2 trading days (days to cover). See the history.
Which famous investors hold OKUR?
2 of the 50 well-known investors we track reported OKUR in their latest 13F filing, including Ken Griffin, Jim Simons. The largest position is worth $1.5M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.